Jimmy Taylor, MD
Hematology & Oncology · Salisbury, MDNPI 1528039898
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,710 and has fallen 89.4% since, to $180 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MD, where the typical reported total is $2,111.
Across 107 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$323
- E.r. Squibb & Sons, L.L.C.$211
- AstraZeneca$192
- Johnson & Johnson$146
- Takeda Pharmaceuticals U.S.A., Inc.$143
- Atricure, Inc.$112
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,38593%
- Education$1797%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $323 |
| E.r. Squibb & Sons, L.L.C. | 3 | $211 |
| AstraZeneca | 9 | $192 |
| Johnson & Johnson | 3 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $143 |
| Atricure, Inc. | 1 | $112 |
| Incyte Corporation | 5 | $106 |
| Genentech USA, Inc. | 5 | $96 |
| Pfizer | 2 | $94 |
| Bristol Myers Squibb | 5 | $90 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $82 |
| Verastem, Inc. | 3 | $71 |
| Seagen Inc. | 3 | $68 |
| Amgen | 3 | $62 |
| Bayer | 3 | $62 |
| AbbVie | 3 | $61 |
| Puma Biotechnology, Inc. | 3 | $58 |
| Dova Pharmaceuticals | 3 | $57 |
| Boehringer Ingelheim | 4 | $56 |
| Gilead | 3 | $53 |
| Dendreon Pharmaceuticals LLC | 2 | $53 |
| Sanofi | 3 | $52 |
| Taiho Oncology, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Partner Therapeutics, Inc. | 1 | $25 |
| AMAG Pharmaceuticals, Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $23 |
| Clovis Oncology, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $18 |
| CSL Behring | 1 | $18 |
| Exelixis Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $14 |
| Secura Bio, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,564 in reported general payments places this provider in the 50th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Salisbury
- Walid El AyassSalisbury$111K
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Arun BhandariAnnapolis$103K
- Huzefa BahrainBaltimore$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.